index.do
Samsung Bioepis is a biopharmaceutical company focused on increasing patient access to high-quality medicines through the development of biosimilars.
www.samsungbioepis.comI don’t have real-time access to live news feeds right now, but I can share a concise snapshot of recent public updates about Samsung Bioepis based on the latest publicly available information up to early 2026.
Core gist
- Samsung Bioepis has ongoing activity around regulatory submissions in the U.S., including FDA reviews for biosimilar candidates such as SB3 (trastuzumab biosimilar) and SB5 (adalimumab biosimilar) with FDA review status noted in early 2026 reporting. This shows continued US regulatory progress for their oncology and immunology biosimilars.[1][2]
- The company has publicized a broad biosimilars pipeline and strategic partnerships, including collaborations with Biogen and potential expansion across ophthalmology and oncology biosimilars, with ongoing or planned INDs and multiple candidates in various stages of development and regulatory review.[3][6]
- Samsung Bioepis has engaged in corporate updates highlighting pipeline goals (targeting multiple biosimilars by 2030) and expansion of manufacturing or development capabilities, including announcements tied to new office spaces and corporate milestones in Korea and abroad.[8][3]
Recent filings and regulatory status (highlights)
- SB5 Adalimumab biosimilar: FDA accepted for review as a BLA, signaling progress toward potential U.S. marketing authorization depending on next regulatory steps and outcomes.[1]
- SB3 Trastuzumab biosimilar: FDA accepted for review under the 351(k) pathway, indicating the United States is a focus for this oncology biosimilar and that Merck/MSD would be involved in commercialization if approved.[2]
Pipeline and strategic context
- Samsung Bioepis outlined plans to secure a broad portfolio of biosimilars by 2030, including candidates in immunology and oncology, with several programs in or advancing through regulatory pathways in major markets like the U.S. and Europe.[3]
- Partnerships and regulatory groundwork for ophthalmology biosimilars (e.g., bevacizumab-related candidates) have been part of public updates, reflecting continued diversification beyond immunology/oncology.[6]
Recent corporate updates (context)
- The company has issued updates at major investor and industry conferences (e.g., J.P. Morgan Healthcare Conference-style briefings) emphasizing pipeline breadth and strategic intent, which is typical for biosimilar players maintaining momentum across multiple therapeutic areas.[3]
Notes and caveats
- News cycles for biosimilars can involve rapid changes in regulatory status, partnering arrangements, and new clinical data. For the exact current status, FDA communications, company press releases, and major financial news outlets should be consulted for the latest confirmations and any new indications or approvals after May 2026.
Would you like me to pull the very latest official press releases or FDA filings specific to SB3 and SB5, and summarize their current statuses with links? I can also provide a quick side-by-side timeline of regulatory milestones for these two candidates.